 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...243244245246247248249250251252253...266267» |
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Tumor-infiltrating lymphocyte, Surgery, Pre-surgery: TOP1201 IPI: Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jan 4, 2017
P2, N=30, Active, not recruiting, Sponsor: Duke University
Trial primary completion date: Nov 2017 --> Mar 2018
- ||||| IMM-101 / Immodulon
New P1/2 trial: Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) - Jan 3, 2017
P1/2, N=300, Not yet recruiting, Sponsor: Immodulon Therapeutics Ltd
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (clinicaltrials.gov) - Dec 29, 2016
P2, N=50, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Nov 2017 --> Mar 2018 Trial primary completion date: Nov 2016 --> Feb 2017
- Tarvacin (bavituximab) / OncXerna Therap, Yervoy (ipilimumab) / BMS
Phase classification, Enrollment change, Trial termination, Metastases: A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (clinicaltrials.gov) - Dec 29, 2016
P1b, N=3, Terminated, Sponsor: University of Texas Southwestern Medical Center
Trial primary completion date: Nov 2016 --> Feb 2017 Phase classification: P1 --> P1b | N=24 --> 3 | Active, not recruiting --> Terminated; standard of care improved combination treatment of ipilimumab plus nivolumab.
- Yervoy (ipilimumab) / BMS
Trial primary completion date, Metastases: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov) - Dec 28, 2016
P=N/A, N=13, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Phase classification: P1 --> P1b | N=24 --> 3 | Active, not recruiting --> Terminated; standard of care improved combination treatment of ipilimumab plus nivolumab. Trial primary completion date: Jun 2017 --> Jun 2016
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Adverse events, Metastases: Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan (clinicaltrials.gov) - Dec 28, 2016
P=N/A, N=2, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2017 --> Jun 2016 Trial primary completion date: Dec 2019 --> Jul 2020
- vopratelimab (JTX-2011) / Concentra Biosci
Enrollment change, PD(L)-1 Biomarker, IO biomarker: ICONIC: JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (clinicaltrials.gov) - Dec 27, 2016
P1/2, N=282, Recruiting, Sponsor: Jounce Therapeutics, Inc.
Trial primary completion date: Dec 2019 --> Jul 2020 N=227 --> 282
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment change: CheckMate 649: Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (clinicaltrials.gov) - Dec 27, 2016
P3, N=1266, Recruiting, Sponsor: Bristol-Myers Squibb
N=227 --> 282 N=870 --> 1266
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial: IMCISION: ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (clinicaltrials.gov) - Dec 27, 2016
P1/2, N=32, Not yet recruiting, Sponsor: The Netherlands Cancer Institute
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD), Yervoy (ipilimumab) / BMS
Trial primary completion date: Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (clinicaltrials.gov) - Dec 27, 2016
P1, N=31, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
N=870 --> 1266 Trial primary completion date: Mar 2017 --> Mar 2016
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, New P2 trial, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: CheckMate 592: An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 22, 2016
P2, N=100, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Oncopore (ruxotemitide) / Verrica
Trial primary completion date, Monotherapy: LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (clinicaltrials.gov) - Dec 22, 2016
P1, N=80, Recruiting, Sponsor: Lytix Biopharma AS
Trial primary completion date: Mar 2017 --> Mar 2016 Trial primary completion date: Dec 2015 --> Oct 2017
- Yervoy (ipilimumab) / BMS
Phase classification, Tumor-specific neoantigens, Metastases: T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=30, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2015 --> Oct 2017 Phase classification: P2 --> P=N/A
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Trial initiation date, Monotherapy, Tumor mutational burden, PD(L)-1 Biomarker: NCI-2016-01004: Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 22, 2016
P2, N=40, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Phase classification: P2 --> P=N/A Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016
- || Yervoy (ipilimumab) / BMS
Enrollment closed, Trial primary completion date, Metastases: PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=1680, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting | Initiation date: Sep 2016 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Feb 2017
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: NCI-2016-00661: Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (clinicaltrials.gov) - Dec 20, 2016
P1/2, N=80, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Feb 2017 Not yet recruiting --> Recruiting
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P3 trial: CheckMate 816: A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Dec 20, 2016
P3, N=326, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Surgery: Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery (clinicaltrials.gov) - Dec 19, 2016
P2, N=4, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=40 --> 4
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Tumor mutational burden: SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov) - Dec 19, 2016
P2, N=334, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=40 --> 4 Phase classification: P=N/A --> P2
- ||||| New P2 trial: FRACTION-RCC: A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Dec 19, 2016
P2, N=650, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (clinicaltrials.gov) - Dec 14, 2016
P1, N=73, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Phase classification: P=N/A --> P2 Trial primary completion date: Feb 2017 --> Aug 2017
- Yervoy (ipilimumab) / BMS
Enrollment change: Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (clinicaltrials.gov) - Dec 13, 2016
P2, N=42, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2017 --> Aug 2017 N=27 --> 42
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New trial, Monotherapy: NICO: Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy (clinicaltrials.gov) - Dec 13, 2016
P=N/A, N=700, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases (clinicaltrials.gov) - Dec 12, 2016
P1/2, N=18, Recruiting, Sponsor: David Minor, MD
N=27 --> 42 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Dec 7, 2016
P3, N=168, Recruiting, Sponsor: The Netherlands Cancer Institute
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Sep 2019
- |||| Erbitux (cetuximab) / Eli Lilly, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Dec 7, 2016
P3, N=490, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2017 --> Sep 2019 Trial primary completion date: Jul 2018 --> Jan 2019
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial: A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (clinicaltrials.gov) - Dec 6, 2016
P2, N=90, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | bempegaldesleukin (NKTR-214) / Nektar Therap, BMS, Ono Pharma
Combination therapy, Metastases: PIVOT-02: A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2016
P1/2, N=30, Recruiting, Sponsor: Nektar Therapeutics
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Phase classification, Trial primary completion date: Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (clinicaltrials.gov) - Dec 5, 2016
P1b, N=136, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jul 2018 --> Jan 2019 Phase classification: P1 --> P1b | Trial primary completion date: Oct 2016 --> Jan 2017
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Checkpoint inhibition: CheckPAC: Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (clinicaltrials.gov) - Dec 5, 2016
P2, N=80, Recruiting, Sponsor: Herlev Hospital
Phase classification: P1 --> P1b | Trial primary completion date: Oct 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P2 trial, PD(L)-1 Biomarker: A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma (clinicaltrials.gov) - Dec 4, 2016
P2, N=60, Not yet recruiting, Sponsor: Assaf-Harofeh Medical Center
- abequolixron (RGX-104) / Inspirna
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer (clinicaltrials.gov) - Dec 2, 2016
P1, N=80, Recruiting, Sponsor: Rgenix, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed: CheckMate 143: A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (clinicaltrials.gov) - Dec 1, 2016
P3, N=440, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Enrollment open: FRACTION-GC: A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer (clinicaltrials.gov) - Dec 1, 2016
P2, N=910, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| renvistobart (BMS-986207) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors (clinicaltrials.gov) - Dec 1, 2016
P1/2, N=170, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, New P2 trial, Monotherapy, Tumor mutational burden: A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab (clinicaltrials.gov) - Dec 1, 2016
P2, N=72, Not yet recruiting, Sponsor: Georgetown University
- ||| Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy, Metastases: ISI-JX: Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (clinicaltrials.gov) - Nov 30, 2016
P1, N=60, Not yet recruiting, Sponsor: Centre Leon Berard
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, New P2 trial, PD(L)-1 Biomarker, IO biomarker: BIONIKK: A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Na (clinicaltrials.gov) - Nov 28, 2016
P2, N=150, Not yet recruiting, Sponsor: Association Pour La Recherche des Th
- || epacadostat (INCB024360) / Incyte
Trial primary completion date, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Nov 27, 2016
P1/2, N=136, Active, not recruiting, Sponsor: Incyte Corporation
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Jan 2017
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Trial primary completion date: Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (clinicaltrials.gov) - Nov 25, 2016
P1, N=44, Active, not recruiting, Sponsor: Duke University
Trial primary completion date: Feb 2016 --> Jan 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2020
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date, Metastases: A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients (clinicaltrials.gov) - Nov 23, 2016
P1/2, N=42, Recruiting, Sponsor: James Graham Brown Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Jun 2020 Trial primary completion date: Dec 2017 --> Dec 2018
- nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Combination therapy: A Phase I/II Study of Intratumoral Injection of SD-101 (clinicaltrials.gov) - Nov 23, 2016
P1/2, N=7, Active, not recruiting, Sponsor: Ronald Levy
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | N=27 --> 7
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical: Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma (clinicaltrials.gov) - Nov 22, 2016
P2, N=25, Not yet recruiting, Sponsor: New York University School of Medicine
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy (clinicaltrials.gov) - Nov 19, 2016
P=N/A, N=323, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=27 --> 7 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
Biomarker, Trial primary completion date, Combination therapy, Metastases: Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-?2b for Melanoma (clinicaltrials.gov) - Nov 16, 2016
P1, N=30, Active, not recruiting, Sponsor: Ahmad Tarhini
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Feb 2018
- Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Metastases: Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Nov 16, 2016
P2, N=8, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Sep 2016 --> Feb 2018 Recruiting --> Active, not recruiting | N=32 --> 8
- |||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker, IO biomarker: CheckMate743: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (clinicaltrials.gov) - Nov 16, 2016
P3, N=600, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=32 --> 8 Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment change, Trial termination, Trial primary completion date, Surgery: SRS (Stereotactic Radiosurgery) Plus Ipilimumab (clinicaltrials.gov) - Nov 15, 2016
P1, N=4, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting --> Recruiting N=30 --> 4 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016; Local IRB required us to submit amendment as a separate study.
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (clinicaltrials.gov) - Nov 15, 2016
P2, N=40, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=30 --> 4 | Suspended --> Terminated | Trial primary completion date: Dec 2016 --> Sep 2016; Local IRB required us to submit amendment as a separate study. Not yet recruiting --> Recruiting
- || Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date, Checkpoint inhibition: CheckPAC: Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (clinicaltrials.gov) - Nov 14, 2016
P2, N=80, Not yet recruiting, Sponsor: Herlev Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2018 --> Nov 2018